Stockreport

Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF NOVATO, Calif. and TOKYO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of no [Read more]